APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Preclinical Assets

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Preclinical Assets Industry Growth and Trends Forecast to 2032

Report ID 174219570116 January 2026113 pages

Choose your research edition.

Industry ResearchPreclinical Assets Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Preclinical Assets Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Preclinical Assets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Preclinical Assets Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Preclinical Assets Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

According to APO Research, the global Preclinical Assets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Preclinical Assets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Preclinical Assets market include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Preclinical Assets market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Preclinical Assets market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Preclinical Assets market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Preclinical Assets.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Preclinical Assets market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Preclinical Assets Market by Company

Eurofins Scientific

Viroclinics Xplore

SGS

Intertek Group

AmplifyBio

IQVIA

ICON plc

Medpace

Pharmatest Services

PPD

Crown Bioscience

Comparative Biosciences

TCG Lifesciences

Domainex

Absorption Systems

Preclinical Assets Segment by Type

Bioanalysis and DMPK Studies

Toxicology Testing

Compound Management

Safety Pharmacology

Others

Preclinical Assets Segment by Application

Biopharmaceutical Companies

Government Institutes

Research institutes

Others

Preclinical Assets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Preclinical Assets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Preclinical Assets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Preclinical Assets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Preclinical Assets companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Preclinical Assets Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Preclinical Assets Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Preclinical Assets Market Share by Region (2021-2026) Table 4. Global Preclinical Assets Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Preclinical Assets Market Share by Region (2027-2032) Table 6. Global Preclinical Assets Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Preclinical Assets Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Preclinical Assets Market Size Share by Type (2021-2026) Table 9. Global Preclinical Assets Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Preclinical Assets Market Size Share Forecasted by Type (2027-2032) Table 11. North America Preclinical Assets Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Preclinical Assets Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Preclinical Assets Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Preclinical Assets Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Preclinical Assets Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Preclinical Assets Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Preclinical Assets Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Preclinical Assets Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Preclinical Assets Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Preclinical Assets Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Preclinical Assets Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Preclinical Assets Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Preclinical Assets Market Size Share by Application (2021-2026) Table 24. Global Preclinical Assets Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Preclinical Assets Market Size Share Forecasted by Application (2027-2032) Table 26. North America Preclinical Assets Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Preclinical Assets Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Preclinical Assets Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Preclinical Assets Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Preclinical Assets Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Preclinical Assets Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Preclinical Assets Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Preclinical Assets Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Preclinical Assets Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Preclinical Assets Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Preclinical Assets Industry Trends Table 37. Preclinical Assets Industry Drivers Table 38. Preclinical Assets Industry Opportunities and Challenges Table 39. Preclinical Assets Industry Restraints Table 40. Global Preclinical Assets Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Preclinical Assets Revenue Market Share by Company (2021-2026) Table 42. Global Preclinical Assets Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Preclinical Assets Key Company Headquarters & Area Served Table 44. Global Preclinical Assets Company, Product Type & Application Table 45. Global Preclinical Assets Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Preclinical Assets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Eurofins Scientific Company Information Table 49. Eurofins Scientific Business Overview Table 50. Eurofins Scientific Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Eurofins Scientific Preclinical Assets Product Portfolio Table 52. Eurofins Scientific Recent Development Table 53. Viroclinics Xplore Company Information Table 54. Viroclinics Xplore Business Overview Table 55. Viroclinics Xplore Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Viroclinics Xplore Preclinical Assets Product Portfolio Table 57. Viroclinics Xplore Recent Development Table 58. SGS Company Information Table 59. SGS Business Overview Table 60. SGS Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. SGS Preclinical Assets Product Portfolio Table 62. SGS Recent Development Table 63. Intertek Group Company Information Table 64. Intertek Group Business Overview Table 65. Intertek Group Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Intertek Group Preclinical Assets Product Portfolio Table 67. Intertek Group Recent Development Table 68. AmplifyBio Company Information Table 69. AmplifyBio Business Overview Table 70. AmplifyBio Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. AmplifyBio Preclinical Assets Product Portfolio Table 72. AmplifyBio Recent Development Table 73. IQVIA Company Information Table 74. IQVIA Business Overview Table 75. IQVIA Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. IQVIA Preclinical Assets Product Portfolio Table 77. IQVIA Recent Development Table 78. ICON plc Company Information Table 79. ICON plc Business Overview Table 80. ICON plc Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. ICON plc Preclinical Assets Product Portfolio Table 82. ICON plc Recent Development Table 83. Medpace Company Information Table 84. Medpace Business Overview Table 85. Medpace Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Medpace Preclinical Assets Product Portfolio Table 87. Medpace Recent Development Table 88. Pharmatest Services Company Information Table 89. Pharmatest Services Business Overview Table 90. Pharmatest Services Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Pharmatest Services Preclinical Assets Product Portfolio Table 92. Pharmatest Services Recent Development Table 93. PPD Company Information Table 94. PPD Business Overview Table 95. PPD Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. PPD Preclinical Assets Product Portfolio Table 97. PPD Recent Development Table 98. Crown Bioscience Company Information Table 99. Crown Bioscience Business Overview Table 100. Crown Bioscience Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Crown Bioscience Preclinical Assets Product Portfolio Table 102. Crown Bioscience Recent Development Table 103. Comparative Biosciences Company Information Table 104. Comparative Biosciences Business Overview Table 105. Comparative Biosciences Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Comparative Biosciences Preclinical Assets Product Portfolio Table 107. Comparative Biosciences Recent Development Table 108. TCG Lifesciences Company Information Table 109. TCG Lifesciences Business Overview Table 110. TCG Lifesciences Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. TCG Lifesciences Preclinical Assets Product Portfolio Table 112. TCG Lifesciences Recent Development Table 113. Domainex Company Information Table 114. Domainex Business Overview Table 115. Domainex Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Domainex Preclinical Assets Product Portfolio Table 117. Domainex Recent Development Table 118. Absorption Systems Company Information Table 119. Absorption Systems Business Overview Table 120. Absorption Systems Preclinical Assets Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Absorption Systems Preclinical Assets Product Portfolio Table 122. Absorption Systems Recent Development Table 123. North America Preclinical Assets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. North America Preclinical Assets Market Size by Country (2021-2026) & (US$ Million) Table 125. North America Preclinical Assets Market Share by Country (2021-2026) Table 126. North America Preclinical Assets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. North America Preclinical Assets Market Share Forecast by Country (2027-2032) Table 128. Europe Preclinical Assets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Europe Preclinical Assets Market Size by Country (2021-2026) & (US$ Million) Table 130. Europe Preclinical Assets Market Share by Country (2021-2026) Table 131. Europe Preclinical Assets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Europe Preclinical Assets Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Preclinical Assets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Preclinical Assets Market Size by Country (2021-2026) & (US$ Million) Table 135. Asia-Pacific Preclinical Assets Market Share by Country (2021-2026) Table 136. Asia-Pacific Preclinical Assets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Asia-Pacific Preclinical Assets Market Share Forecast by Country (2027-2032) Table 138. Latin America Preclinical Assets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Latin America Preclinical Assets Market Size by Country (2021-2026) & (US$ Million) Table 140. Latin America Preclinical Assets Market Share by Country (2021-2026) Table 141. Latin America Preclinical Assets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Latin America Preclinical Assets Market Share Forecast by Country (2027-2032) Table 143. Middle East & Africa Preclinical Assets Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East & Africa Preclinical Assets Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East & Africa Preclinical Assets Market Share by Country (2021-2026) Table 146. Middle East & Africa Preclinical Assets Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East & Africa Preclinical Assets Market Share Forecast by Country (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Preclinical Assets Product Image Figure 3. Global Preclinical Assets Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Preclinical Assets Market Size (2021-2032) & (US$ Million) Figure 5. Global Preclinical Assets Market Share by Region: 2025 VS 2032 Figure 6. Global Preclinical Assets Market Share by Region (2021-2032) Figure 7. North America Preclinical Assets Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Preclinical Assets Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Preclinical Assets Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Preclinical Assets Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Preclinical Assets Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Bioanalysis and DMPK Studies Image Figure 13. Global Bioanalysis and DMPK Studies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Toxicology Testing Image Figure 15. Global Toxicology Testing Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Compound Management Image Figure 17. Global Compound Management Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Safety Pharmacology Image Figure 19. Global Safety Pharmacology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Others Image Figure 21. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Preclinical Assets Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Preclinical Assets Market Share by Type 2025 VS 2032 Figure 24. North America Preclinical Assets Market Size Share by Type (2021-2032) Figure 25. Europe Preclinical Assets Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Preclinical Assets Market Size Share by Type (2021-2032) Figure 27. Latin America Preclinical Assets Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Preclinical Assets Market Size Share by Type (2021-2032) Figure 29. Biopharmaceutical Companies Image Figure 30. Global Biopharmaceutical Companies Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Government Institutes Image Figure 32. Global Government Institutes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Research institutes Image Figure 34. Global Research institutes Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Others Image Figure 36. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global Preclinical Assets Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Preclinical Assets Market Share by Application 2025 VS 2032 Figure 39. North America Preclinical Assets Market Size Share by Application (2021-2032) Figure 40. Europe Preclinical Assets Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific Preclinical Assets Market Size Share by Application (2021-2032) Figure 42. Latin America Preclinical Assets Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa Preclinical Assets Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 Preclinical Assets Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America Preclinical Assets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America Preclinical Assets Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America Preclinical Assets Market Share by Country (2021-2032) Figure 49. Europe Preclinical Assets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Preclinical Assets Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Preclinical Assets Market Share by Country (2021-2032) Figure 52. Asia-Pacific Preclinical Assets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific Preclinical Assets Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific Preclinical Assets Market Share by Country (2021-2032) Figure 55. Latin America Preclinical Assets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Preclinical Assets Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Preclinical Assets Market Share by Country (2021-2032) Figure 58. Middle East & Africa Preclinical Assets Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa Preclinical Assets Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa Preclinical Assets Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • Bioanalysis and DMPK Studies
  • Toxicology Testing
  • Compound Management
  • Safety Pharmacology
  • Others
Applications
  • Biopharmaceutical Companies
  • Government Institutes
  • Research institutes
  • Others
Companies covered
  • Eurofins Scientific
  • Viroclinics Xplore
  • SGS
  • Intertek Group
  • AmplifyBio
  • IQVIA
  • ICON plc
  • Medpace
  • Pharmatest Services
  • PPD
  • Crown Bioscience
  • Comparative Biosciences
  • TCG Lifesciences
  • Domainex
  • Absorption Systems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Preclinical Assets Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Preclinical Assets Market Size by Region (2021-2032)
  5. 1.4.1 Global Preclinical Assets Market Size by Region (2021-2026)
  6. 1.4.2 Global Preclinical Assets Market Size by Region (2027-2032)
  7. 1.5 Key Regions Preclinical Assets Market Size (2021-2032)
  8. 1.5.1 North America Preclinical Assets Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Preclinical Assets Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Preclinical Assets Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Preclinical Assets Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Preclinical Assets Market Size Growth Rate (2021-2032)
2 Preclinical Assets Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Bioanalysis and DMPK Studies
  3. 2.1.2 Toxicology Testing
  4. 2.1.3 Compound Management
  5. 2.1.4 Safety Pharmacology
  6. 2.1.5 Others
  7. 2.2 Global Preclinical Assets Market Size by Type
  8. 2.2.1 Global Preclinical Assets Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Preclinical Assets Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Preclinical Assets Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Preclinical Assets Market Size by Regions
  12. 2.3.1 North America Preclinical Assets Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Preclinical Assets Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Preclinical Assets Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Preclinical Assets Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Preclinical Assets Market Size Breakdown by Type (2021-2026)
3 Preclinical Assets Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Biopharmaceutical Companies
  3. 3.1.2 Government Institutes
  4. 3.1.3 Research institutes
  5. 3.1.4 Others
  6. 3.2 Global Preclinical Assets Market Size by Application
  7. 3.2.1 Global Preclinical Assets Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Preclinical Assets Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Preclinical Assets Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Preclinical Assets Market Size by Regions
  11. 3.3.1 North America Preclinical Assets Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Preclinical Assets Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Preclinical Assets Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Preclinical Assets Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Preclinical Assets Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Preclinical Assets Industry Trends
  2. 4.2 Preclinical Assets Industry Drivers
  3. 4.3 Preclinical Assets Industry Opportunities and Challenges
  4. 4.4 Preclinical Assets Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Preclinical Assets Revenue (2021-2026)
  2. 5.2 Global Preclinical Assets Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Preclinical Assets Key Company Headquarters & Area Served
  4. 5.4 Global Preclinical Assets Company, Product Type & Application
  5. 5.5 Global Preclinical Assets Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Preclinical Assets Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Preclinical Assets Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Preclinical Assets Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Eurofins Scientific
  2. 6.1.1 Eurofins Scientific Company Information
  3. 6.1.2 Eurofins Scientific Business Overview
  4. 6.1.3 Eurofins Scientific Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Eurofins Scientific Preclinical Assets Product Portfolio
  6. 6.1.5 Eurofins Scientific Recent Developments
  7. 6.2 Viroclinics Xplore
  8. 6.2.1 Viroclinics Xplore Company Information
  9. 6.2.2 Viroclinics Xplore Business Overview
  10. 6.2.3 Viroclinics Xplore Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Viroclinics Xplore Preclinical Assets Product Portfolio
  12. 6.2.5 Viroclinics Xplore Recent Developments
  13. 6.3 SGS
  14. 6.3.1 SGS Company Information
  15. 6.3.2 SGS Business Overview
  16. 6.3.3 SGS Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 SGS Preclinical Assets Product Portfolio
  18. 6.3.5 SGS Recent Developments
  19. 6.4 Intertek Group
  20. 6.4.1 Intertek Group Company Information
  21. 6.4.2 Intertek Group Business Overview
  22. 6.4.3 Intertek Group Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Intertek Group Preclinical Assets Product Portfolio
  24. 6.4.5 Intertek Group Recent Developments
  25. 6.5 AmplifyBio
  26. 6.5.1 AmplifyBio Company Information
  27. 6.5.2 AmplifyBio Business Overview
  28. 6.5.3 AmplifyBio Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 AmplifyBio Preclinical Assets Product Portfolio
  30. 6.5.5 AmplifyBio Recent Developments
  31. 6.6 IQVIA
  32. 6.6.1 IQVIA Company Information
  33. 6.6.2 IQVIA Business Overview
  34. 6.6.3 IQVIA Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 IQVIA Preclinical Assets Product Portfolio
  36. 6.6.5 IQVIA Recent Developments
  37. 6.7 ICON plc
  38. 6.7.1 ICON plc Company Information
  39. 6.7.2 ICON plc Business Overview
  40. 6.7.3 ICON plc Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 ICON plc Preclinical Assets Product Portfolio
  42. 6.7.5 ICON plc Recent Developments
  43. 6.8 Medpace
  44. 6.8.1 Medpace Company Information
  45. 6.8.2 Medpace Business Overview
  46. 6.8.3 Medpace Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Medpace Preclinical Assets Product Portfolio
  48. 6.8.5 Medpace Recent Developments
  49. 6.9 Pharmatest Services
  50. 6.9.1 Pharmatest Services Company Information
  51. 6.9.2 Pharmatest Services Business Overview
  52. 6.9.3 Pharmatest Services Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Pharmatest Services Preclinical Assets Product Portfolio
  54. 6.9.5 Pharmatest Services Recent Developments
  55. 6.10 PPD
  56. 6.10.1 PPD Company Information
  57. 6.10.2 PPD Business Overview
  58. 6.10.3 PPD Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 PPD Preclinical Assets Product Portfolio
  60. 6.10.5 PPD Recent Developments
  61. 6.11 Crown Bioscience
  62. 6.11.1 Crown Bioscience Company Information
  63. 6.11.2 Crown Bioscience Business Overview
  64. 6.11.3 Crown Bioscience Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Crown Bioscience Preclinical Assets Product Portfolio
  66. 6.11.5 Crown Bioscience Recent Developments
  67. 6.12 Comparative Biosciences
  68. 6.12.1 Comparative Biosciences Company Information
  69. 6.12.2 Comparative Biosciences Business Overview
  70. 6.12.3 Comparative Biosciences Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Comparative Biosciences Preclinical Assets Product Portfolio
  72. 6.12.5 Comparative Biosciences Recent Developments
  73. 6.13 TCG Lifesciences
  74. 6.13.1 TCG Lifesciences Company Information
  75. 6.13.2 TCG Lifesciences Business Overview
  76. 6.13.3 TCG Lifesciences Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 TCG Lifesciences Preclinical Assets Product Portfolio
  78. 6.13.5 TCG Lifesciences Recent Developments
  79. 6.14 Domainex
  80. 6.14.1 Domainex Company Information
  81. 6.14.2 Domainex Business Overview
  82. 6.14.3 Domainex Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Domainex Preclinical Assets Product Portfolio
  84. 6.14.5 Domainex Recent Developments
  85. 6.15 Absorption Systems
  86. 6.15.1 Absorption Systems Company Information
  87. 6.15.2 Absorption Systems Business Overview
  88. 6.15.3 Absorption Systems Preclinical Assets Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Absorption Systems Preclinical Assets Product Portfolio
  90. 6.15.5 Absorption Systems Recent Developments
7 North America
  1. 7.1 North America Preclinical Assets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Preclinical Assets Market Size by Country (2021-2026)
  3. 7.3 North America Preclinical Assets Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Preclinical Assets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Preclinical Assets Market Size by Country (2021-2026)
  3. 8.3 Europe Preclinical Assets Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Preclinical Assets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Preclinical Assets Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Preclinical Assets Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Preclinical Assets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Preclinical Assets Market Size by Country (2021-2026)
  3. 10.3 South America Preclinical Assets Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Preclinical Assets Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Preclinical Assets Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Preclinical Assets Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst